Maximize your thought leadership

Multiplatform Study Compares Da Vinci Xi, Hugo RAS, and Versius in Colon Cancer Surgery

By Burstable Health Team
A new study comparing three robotic surgical platforms for colon cancer surgery found that the Da Vinci Xi system had fewer conversions to laparoscopy or open surgery compared to Hugo RAS and Versius, though all platforms were feasible for expert surgeons.
Multiplatform Study Compares Da Vinci Xi, Hugo RAS, and Versius in Colon Cancer Surgery

A prospective study published in Laparoscopic, Endoscopic and Robotic Surgery has compared the performance of three robotic surgical platforms—Da Vinci Xi, Hugo™ RAS, and Versius®—in colon cancer surgery. The COMPAR-CRC multiplatform study, conducted by researchers in Europe, provides some of the first direct clinical evidence comparing these systems in colorectal procedures.

The exploratory study enrolled 45 consecutive adult patients undergoing robotic colon resection between February and December 2024. Two experienced colorectal surgeons performed all procedures across two surgical units, with each robotic platform used in 15 cases. The mean patient age was 66.8 years, and 68.9% underwent surgery for colon cancer.

Results showed notable differences in conversion rates: no conversions to laparoscopy or open surgery occurred in the Da Vinci group, while two conversions were recorded with Hugo™ RAS and three with Versius®. One intra-operative instrument malfunction occurred with Hugo™ RAS, and one surgical complication was reported in each group. The study also found that Versius® cases required more frequent use of laparoscopic energy devices (p < 0.001), and Hugo™ RAS was associated with longer total operating room time (p = 0.022) and longer incision length (p = 0.005).

Despite these differences, no significant disparities emerged in post-operative recovery or oncological outcomes. The researchers concluded that robotic colorectal surgery with all three platforms is feasible when performed by expert surgeons, but they emphasized the need for larger comparative trials to confirm differences in recovery and oncological efficacy.

The findings are particularly relevant as the adoption of robotic surgery expands beyond the established Da Vinci system. Hugo™ RAS and Versius® are newer CE-marked platforms entering the European market, offering potential alternatives for hospitals and surgeons. However, this study suggests that the Da Vinci system may have advantages in terms of fewer conversions and less reliance on additional laparoscopic tools, which could translate into more efficient procedures.

The full study is available online at https://doi.org/10.1016/j.lers.2025.10.001.

Burstable Health Team

Burstable Health Team

@burstable

Burstable News™ is a hosted solution designed to help businesses build an audience and enhance their AIO and SEO press release strategies by automatically providing fresh, unique, and brand-aligned business news content. It eliminates the overhead of engineering, maintenance, and content creation, offering an easy, no-developer-needed implementation that works on any website. The service focuses on boosting site authority with vertically-aligned stories that are guaranteed unique and compliant with Google's E-E-A-T guidelines to keep your site dynamic and engaging.